Related Experiment Video

Updated: Feb 23, 2026

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

1.7K

Prostate Cancer Screening: Time to Question How to Optimize the Ratio of Benefits and Harms

Andrew J Vickers1

  • 1From Memorial Sloan Kettering Cancer Center, New York, New York.

Annals of Internal Medicine
|September 5, 2017
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
08:05

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

1.3K
Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
05:35

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Published on: June 6, 2025

1.8K

Related Experiment Videos

Last Updated: Feb 23, 2026

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

1.7K
Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
08:05

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

1.3K
Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
05:35

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Published on: June 6, 2025

1.8K

Related Concept Videos

Hazard Ratio01:12

Hazard Ratio

652
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
652
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

500
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
500

Articles linked to this work by shared authors, journal, and citation graph.

Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection.

European urology·2024

Successful completion of large, low-cost randomized cancer trials at an academic cancer center.

Clinical trials (London, England)·2024

Testosterone Therapy in Men After Radical Prostatectomy for Low-Intermediate Organ-Confined Prostate Cancer.

The Journal of urology·2024

Clinical utility of an artificial intelligence radiomics-based tool for risk stratification of pulmonary nodules.

JNCI cancer spectrum·2024

Oncologic Outcomes of Incidental Versus Biopsy-diagnosed Grade Group 1 Prostate Cancer: A Multi-institutional Study.

European urology open science·2024

Quantification of Gleason Pattern 4 Metrics Identifies Pathologic Progression in Patients With Grade Group 2 Prostate Cancer on Active Surveillance.

Clinical genitourinary cancer·2024

Overuse and False Restraint in Large Language Model Recommendations for Choosing Wisely Scenarios.

Annals of internal medicine·2026

Diagnosis and Treatment of Cardiovascular Conditions in Medicare Advantage In-Home Health Risk Assessments.

Annals of internal medicine·2026

Projected Effect of 2026 Federal Changes to the Childhood Immunization Schedule on Chronic Hepatitis B Virus Infections in the United States.

Annals of internal medicine·2026

Dual use of e-cigarettes and combustible cigarettes elevates salivary DKK1 levels similar to exclusive smoking.

Frontiers in public health·2026

scTIME: single-cell-informed interpretable modeling of immunotherapy-associated immune states in non-small cell lung cancer.

Frontiers in artificial intelligence·2026

High-volume cervical lymph node metastasis in papillary thyroid carcinoma: development and external validation of an interpretable prediction model.

Frontiers in oncology·2026

Development of the LARyNGTH score to predict central neurogenic respiratory failure in lateral medullary infarction.

Frontiers in neurology·2026

Predictive value of multimodal models combining CT body composition and clinical variables for short-term postoperative complications in colorectal cancer: a systematic review and meta-analysis.

Frontiers in nutrition·2026

Ocrelizumab Wearing-Off Phenomenon: Prevalence, Predictors, and Outcomes After Intervention.

International journal of MS care·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us